Nyxoah's U.S. Launch Accelerates as Reimbursement Tailwind Firms Up
Q1 2026 sees 25% sequential U.S. revenue growth, a 100% prior-auth approval rate, and a CPT coding roadmap that de-risks the Genio system's path to scale.
NYXH · Earnings Call · 2026-05-12
A Launch That Exceeds Expectations
Nyxoah's first-quarter 2026 earnings call marked a clear inflection point: the company is no longer a pre-commercial story, but a commercial execution play with real revenue traction. Olivier Taelman, CEO, opened by highlighting the decisive metric: “we delivered on our commitment to drive 25% sequential U. S. Revenue growth” — Olivier Taelman, Chief Executive Officer · 2026-05-12. This came alongside a 13% sequential worldwide revenue increase, and the company guided full-year 2026 revenue to €36–40 million, comfortably above street expectations. The U.S. launch is gaining momentum across all its leading indicators. Nyxoah expanded its field force to 40 fully operational sales reps, enabling coverage of 200 of the 400 high-volume hypoglossal neurostimulation accounts. The trained surgeon base grew to 207, and active accounts climbed to 91. But the most encouraging number may be the patient funnel: 241 patients were pending prior authorization at quarter-end, with a 100% approval rate on reviewed submissions. As Olivier explained in Q&A, “so far, we have a 100% prior authorization approval rate” — Olivier Taelman, Chief Executive Officer · 2026-05-12. This is not just a metric—it reflects the Sleep medicine referral strategy paying off, and the appetite among surgeon training cohorts to adopt Genio. The company's own Market research reinforced this: 88% of ENTs want multiple hypoglossal stimulation options, and 84% collaborate with sleep medicine colleagues to manage AGNS patients. This confirms the strategic bet on partnering with sleep physicians, a differentiator vs. the traditional ENT-led model.Reimbursement: From Overhang to Optionality
The biggest overhang on the stock has always been reimbursement. That cloud is lifting. The CMS issued AGNS-specific C-codes in February, providing facility payment parity with existing codes. The company also reported 100% approval under the new AI-supported WISER prior-auth program. Commercial payers, representing ~90% of cases, continue to cover both CPT 64568 and 64582. The reimbursement picture is now concrete, and management is already looking ahead to 2028. As Olivier noted in the Q&A:This is a far cry from the uncertainty of prior quarters. The company is now actively engaged with the CPT editorial panel and specialty societies, and the competitive dynamics with Inspire are shifting. The AGNS technology landscape is evolving, and Nyxoah is positioning itself to benefit from a potential dedicated code or a broader coding umbrella. The shift in keyword trajectory is telling: this quarter's top keywords center on CPT code, C code, and "editorial panel," replacing the clinical-data-driven themes (DREAM, ACCCESS) of earlier calls. Reimbursement is no longer an abstract risk—it's a tangible, managed process.For 2028, we understand that there are currently 2 paths to support continued coding being dedicated CPT codes, for the different AGNS technologies, or creating a comprehensive AGNS coding set...
Margins and Cash: The New Watchpoints
With reimbursement de-risked, the market's attention turns to profitability and cash. The company guided to 60–62% gross margins for 2026, but Q1 came in at 57% due to production yield issues. CFO John Landry explained: “production yield issues in the quarter, which have been addressed” — John Landry, Chief Financial Officer · 2026-05-12. In Q&A, he offered more detail:Management is confident margins will recover to the low-60s in the back half, and the Genio 2.2 disposable patch and activation chip, launching early 2027, should provide a step-change to 70%+. Combined with volume-based cost reductions from contract manufacturers, the long-term path to 80%+ gross margins remains intact. On cash, the company held €25.9 million at quarter-end, with an additional €13.8 million expected from the European Investment Bank tranche. Non-GAAP cash operating expenses were held flat at €21.7 million, even as the company added 15 sales reps—a sign of disciplined capital allocation. Still, with a market cap just ~$125 million, cash runway is a live concern. The company targets revenue breakeven at €150 million, and it believes it can get there with roughly €100 million of additional capital. That's a steep hill for a small cap, but the execution so far—25% sequential growth, 100% prior-auth approval, and a clear reimbursement path—gives credence to the story.we did have some issues with production yields in the quarter due to some turnover and some training issues, which have been all resolved, at this point.